Keywords : animal vaccine, Vaccine, poultry vaccine, Newcastle disease vaccine
Animal vaccine sales amount in China was about CNY 7.11 billion (excluding net imports); the sales amount of swine vaccine and poultry vaccines were CNY 3.51 billion and 3.01 billion respectively, accounting for 49.4% and 42.3% of the total sales amount respectively. The market scale of China's animal vaccine is nearly CNY 10 billion in 2012. Although there are nearly 60 animal vaccine manufacturers in China, the market share is concentra...
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
- Publication date: January 2013
- Report size: 85 pages
- Report price: $ 2 100
Animal vaccine sales amount in China was about CNY 7.11 billion (excluding net imports); the sales amount of swine vaccine and poultry vaccines were CNY 3.51 billion and 3.01 billion respectively, accounting for 49.4% and 42.3% of the total sales amount respectively. The market scale of China's animal vaccine is nearly CNY 10 billion in 2012.
Although there are nearly 60 animal vaccine manufacturers in China, the market share is concentrated in the hands of a few corporations. CAHIC, Qingdao Yebio Bioengineering Co. Ltd., Dahuanong, TECON and Chengdu TECBOND are the representatives of China’s animal vaccine industry. The five enterprises accounted for 37.9% of China’s animal vaccine market in the first half of 2012.
Among the key animal vaccine manufacturers in China, China Animal Husbandry Industry Co., Ltd (CAHIC) obtained the highest business income in the first half of 2012—CNY 964 million, accounting for 14.3% market share. TECON, Dahuanong and Jinyu Group also had more than 5% market share respectively. The sales of these companies mainly came from the national mandatory vaccine procurement policy. The proportion of the national mandatory vaccine procurement accounted for 82.7% of CAHIC’s total income in the first half of 2012.
In recent years, animal mandatory immunization coverage is gradually expanded in China. Restricted by the economic conditions, compulsory vaccination epidemics only cover five kinds of animal disease. While there are about 17 kinds of animal diseases; other diseases also have great hazard. With farming enterprises and farmers enhanced emphasis on the prevention and control of animal diseases, the demand of conventional vaccine at their own expense will be further improved in the future. Swine and poultry are the main species in China’s livestock breeding, newcastle disease vaccine and porcine circovirus vaccine will be the two conventional vaccines with very good market prospects.
Drug And Medication Industry in China
1. Development Environment of China’s Animal Vaccine Industry
1.1 Market Characteristics
1.1.1 Industry Definition
1.1.2 Industry Characteristics
1.2 Economic Environment
1.2.1 Economic Development Status
1.2.2 GDP
1.2.3 Fixed Asset Investment
1.2.4 Import and Export Amount and Growth Rate
1.3 Policy Environment
1.3.1 Industry Related Policy
1.3.2 Effect of Related Policy
2. Technology Development of China’s Animal Vaccine Industry
2.1 Product Technology Maturity
2.2 Technology Gap between China and Foreign Countries and Main Reasons
2.3 Strategy for Improving China’s Technology
3. Development of China’s Animal Vaccine Industry
3.1 Swine Vaccine
3.2 Poultry Vaccines
3.3 Pet Vaccines
4. Economic Operation of Animal Vaccine Industry
4.1 Industry Production and Sales, 2007-2012
4.2 Industry Scale, 2007-2012
4.3 Industry Profitability in 2011
4.4 Industry Business Development Capacity in 2011
4.5 Industry Debt Paying Ability in 2011
5. Import and Export of China’s Animal Vaccine
5.1 Import
5.2 Export
6. Effect of Industry Competition Landscape on Investment in China, 2012
6.1 Michael Porter Five Forces Analysis of China’s Animal Vaccine Industry
6.1.1 Competition between the Existing Enterprises
6.1.2 Potential New Entrant
6.1.3 Substitute
6.1.4 Bargaining Power of Supplier
6.1.5 Bargaining Power of Customers
6.2 Competition Landscape of China’s Animal Vaccine Industry
6.3 Competition Forecast of China’s Animal Vaccine Industry
7. Domestic Key Enterprises, 2011-2012
7.1 China Animal Husbandry Industry Co., Ltd. (CAHIC)
7.1.1 Company Profile
7.1.2 Business Performance
7.1.3 Company Competitiveness
7.1.4 Development Strategy
7.2 Inner Mongolia Jinyu Group Stock Company
7.2.1 Company Profile
7.2.2 Business Performance
7.2.3 Company Competitiveness
7.2.4 Development Strategy
7.3 TECON
7.3.1 Company Profile
7.3.2 Business Performance
7.3.3 Company Competitiveness
7.3.4 Development Strategy
7.4 Chengdu TECBOND Biological Products Co. Ltd.
7.4.1 Company Profile
7.4.2 Business Performance
7.4.3 Company Competitiveness
7.4.4 Development Strategy
7.5 Guangdong Dahuanong Animal Health Products Co. Ltd.
7.5.1 Company Profile
7.5.2 Business Performance
7.5.3 Company Competitiveness
7.5.4 Development Strategy
8. Investment Analysis of Animal Vaccine Industry, 2013-2017
8.1 Investment Opportunity
8.2 Investment Risk
8.2.1 Policy Risk
8.2.2 Market Risk
8.2.3 Application Risk
8.2.4 Technology Risk
8.3 Industry Barriers to Entry
8.3.1 Administrative Barriers to Entry
8.3.2 Technical Barrier
8.3.3 Brand Barrier
8.3.4 Management Barrier
8.3.5 Financial Barrier
8.4 Industry Investment Proposals
9. Investment Opportunity and Risk of Animal Vaccine Industry
9.1 Investment Opportunity of China’s Animal Vaccine Industry
9.1.1 Investment Opportunity
9.1.2 Feasibility Study
9.2 Investment Efficiency of Animal Vaccine Industry
9.2.1 Investment Status in 2012
9.2.2 Investment Efficiency in 2012
9.2.3 Investment Trend Forecast 2013-2017
9.2.4 Investment Orientation, 2013-2017
Companies Mentioned
China Animal Husbandry Industry Co., Ltd. (CAHIC)
Inner Mongolia Jinyu Group Stock Company
TECON
Chengdu TECBOND Biological Products Co. Ltd.
Guangdong Dahuanong Animal Health Products Co. Ltd.
Vaccine in China
- $ 250
- Industry data
- January 2013
Yearly, From 2003 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI
- Industries : Drug and Medication
- Countries : China
- $ 250
- Industry data
- January 2013
Yearly, From 2002 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI
- Industries : Drug and Medication
- Countries : China
- $ 250
- Industry data
- January 2013
Yearly, From 2003 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI
- Industries : Drug and Medication
- Countries : China
- $ 250
- Industry data
- January 2013
Yearly, From 2003 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI
- Industries : Drug and Medication
- Countries : China
- $ 250
- Industry data
- January 2013
Yearly, From 2002 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI
- Industries : Drug and Medication
- Countries : China
Drug and Medication in China
- $ 250
- Industry data
- May 2013
Yearly, From 2006 To 2011
By Chinascope Financial
Source: Chinascope Financial
- Industries : Drug and Medication
- Countries : China
- $ 250
- Industry data
- January 2013
Yearly, From 2004 To 2021
By Business Monitor International
Source: Southern Medicine Economic Institute (SMEI), Association of the European Self-Medication Society (AE
- Industries : Drug and Medication
- Countries : China
- $ 250
- Industry data
- January 2013
Yearly, From 2005 To 2021
By Business Monitor International
Source: Southern Medicine Economic Institute (SMEI), Association of the European Self-Medication Society (AE
- Industries : Drug and Medication
- Countries : China
- $ 250
- Industry data
- January 2013
Yearly, From 2004 To 2021
By Business Monitor International
Source: Southern Medicine Economic Institute (SMEI), Association of the European Self-Medication Society (AE
- Industries : Drug and Medication
- Countries : China
- $ 250
- Industry data
- January 2013
Yearly, From 2005 To 2021
By Business Monitor International
Source: Southern Medicine Economic Institute (SMEI), Association of the European Self-Medication Society (AE
- Industries : Drug and Medication
- Countries : China
- Publication date: January 2013
- Report size: 85 pages
- Report price: $ 2 100
